Published in Can J Urol on February 01, 2011
The incidence of prostate cancer and urothelial cancer in the prostate in cystoprostatectomy specimens in a tertiary care Canadian centre. Can Urol Assoc J (2013) 1.41
EDITORIAL COMMENT Re: Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma. Can J Urol (2011) 0.75
European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93
Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res (2010) 2.23
Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. Eur Urol (2008) 2.04
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Laparoscopic kidney transplantation. Eur Urol (2009) 1.68
Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol (2008) 1.65
Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.63
DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol (2009) 1.59
Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int (2012) 1.58
Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol (2011) 1.55
Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol (2007) 1.55
Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU Int (2012) 1.50
Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology (2009) 1.47
Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int (2011) 1.23
Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol (2006) 1.14
Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol (2011) 1.05
Prognostic factors in penile cancer. Urology (2010) 1.05
CT findings in urinary diversion after radical cystectomy: postsurgical anatomy and complications. Radiographics (2009) 1.04
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Conservative surgical therapy for leydig cell tumor. J Urol (2007) 1.02
Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol (2010) 1.01
Primary congenital bladder diverticula in children. Urology (2007) 0.98
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol (2004) 0.98
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol (2005) 0.92
Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol (2014) 0.92
Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol (2012) 0.90
The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol (2010) 0.90
Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet (2007) 0.89
A re-adjustable sling for female recurrent stress incontinence and sphincteric deficiency: Outcomes and complications in 125 patients using the Remeex sling system. Neurourol Urodyn (2010) 0.88
Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol (2010) 0.87
Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology (2011) 0.86
Hemangioma of the prostatic urethra: holmium laser treatment. Urol Int (2008) 0.86
Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol (2012) 0.86
Prepubertal testicular tumours and efficacy of testicular preserving surgery. BJU Int (2010) 0.85
Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU Int (2012) 0.85
Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol (2010) 0.84
Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010. BJU Int (2012) 0.84
Primary obstructive megaureter: initial experience with endoscopic dilatation. J Endourol (2007) 0.83
[Practical guideline for the management of adverse events associated with BCG installations]. Arch Esp Urol (2008) 0.83
Detrusor quantitative morphometry in obstructed males and controls. J Urol (2006) 0.83
Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer. BJU Int (2004) 0.82
Efficiency of endoscopic treatment for vesico-ureteric reflux in adults. BJU Int (2008) 0.82
[Bilateral laparoscopic nephrectomy for renal cancer]. Arch Esp Urol (2004) 0.82
A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PLoS One (2013) 0.82
Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients. Eur Urol (2007) 0.81
Laparoscopic management of spontaneous retroperitoneal hemorrhage. Urol Int (2011) 0.81
Embolization of a bleeding aneurysm in a patient with spontaneous perirenal haematoma due to Polyarteritis nodosa. Arch Esp Urol (2005) 0.81
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology (2008) 0.80
Laparoscopic live donor nephrectomy with the use of 3-mm instruments and laparoscope: initial experience at a tertiary center. Eur Urol (2011) 0.80
Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer. Curr Opin Urol (2012) 0.80
[Lithiasis in complete ureteral duplication and prostate cancer: combined surgery treatment]. Arch Ital Urol Androl (2003) 0.80
[The presence of a prolene mesh in the vagina]. Arch Esp Urol (2006) 0.80
[Early ultrasound detection of renal tumors in patients with end stage renal disease in dialysis]. Arch Esp Urol (2007) 0.80
Second to fourth digit ratio, adult testosterone level and testosterone deficiency. BJU Int (2011) 0.79
Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol (2003) 0.79
Higher second fourth digit ratio predicts higher incidence of prostate cancer in prostate biopsy. Arch Esp Urol (2012) 0.79
Disseminated retroperitoneal choriocarcinoma with open fistula to intestine. "Restitutio ad integrum" with chemotherapy alone. Clin Transl Oncol (2006) 0.79
Is bladder cycling useful in the urodynamic evaluation previous to renal transplantation? Urol Int (2005) 0.78
Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy. J Urol (2011) 0.78
The road to real zero ischemia for partial nephrectomy. J Endourol (2013) 0.78
[Vesico-ureteral reflux, endoscopic management]. Arch Argent Pediatr (2013) 0.77
Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy. World J Urol (2011) 0.77
Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int (2012) 0.77
Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol (2004) 0.76
[Percutaneous treatment of a primary renal aspergilloma in a patient with AIDS]. Arch Ital Urol Androl (2003) 0.76
Re: Markus J. Bader, Ronald Sroka, Christian Gratzke, et al. Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol 2009;56:65-71. Eur Urol (2009) 0.75
Re: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol (2002) 0.75
[Renal artery aneurysm]. Arch Esp Urol (2007) 0.75
[Thyroid metastasis of a renal carcinoma. Case report]. Arch Esp Urol (2006) 0.75
The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer. Eur Urol (2003) 0.75
[Allogeneic transplantation of peripheral blood hematopoietic stem-cells with low intensity conditioning for the treatment of a metastatic clear cell carcinoma. Preliminary results after two years of follow-up]. Arch Esp Urol (2006) 0.75
[Mixed transitional cell and small cell carcinoma of the bladder with metastases with neuroendocrine histology only. Case report and bibliography review]. Arch Esp Urol (2007) 0.75
Kidney transplants in patients with bladder augmentation: correlation and evolution. Int Urol Nephrol (2007) 0.75
[Paraurethral cyst of the Littre's gland: an exceptional case]. Arch Esp Urol (2006) 0.75
[High flow priapism. Case report]. Arch Esp Urol (2006) 0.75
Early experience of a living donor kidney transplant program. Eur Urol (2006) 0.75
[Protocol for ureteroscopy in the diagnosis and treatment of the upper urinary tract transitional cell carcinoma]. Arch Esp Urol (2004) 0.75
Mucosal fold as a mechanical cause of obstruction in orthotopic ileal neobladder. Arch Ital Urol Androl (2004) 0.75